The estimated Net Worth of Donald A. Kalkofen is at least $52.6 Mille dollars as of 3 December 2019. Mr. Kalkofen owns over 1,175 units of Protagonist Therapeutics Inc stock worth over $52,628 and over the last 5 years he sold PTGX stock worth over $0. In addition, he makes $0 as Chief Financial Officer e Principal Financial Officer and Principal Accounting Officer at Protagonist Therapeutics Inc.
Donald has made over 1 trades of the Protagonist Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 1,175 units of PTGX stock worth $5,993 on 3 December 2019.
The largest trade he's ever made was buying 1,175 units of Protagonist Therapeutics Inc stock on 3 December 2019 worth over $5,993. On average, Donald trades about 235 units every 0 days since 2019. As of 3 December 2019 he still owns at least 1,175 units of Protagonist Therapeutics Inc stock.
You can see the complete history of Mr. Kalkofen stock trades at the bottom of the page.
Donald A. Kalkofen serves as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of the Company. He has served as the Company's Chief Financial Officer since May 2019, after serving in a consulting capacity as the Company's Senior Advisor, Finance since February 11, 2019 until his appointment as Chief Financial Officer. He previously served in a consulting capacity as Interim Controller of the Company from May 2018 to June 2018. He served as Interim Chief Financial Officer of App Annie, Inc., a global SaaS company, from June 2018 to January 2019. From November 2017 until April 2018. Mr. Kalkofen served as a Financial Consultant at Depomed, Inc. (now Assertio Therapeutics, Inc.), a specialty pharmaceutical company. He also served as a Chief Financial Officer consulting partner at Hardesty, LLC, a financial executive consulting firm, from July 2016 to November 2018. Mr. Kalkofen served at Align Technology, Inc., a global medical device company, as Interim Assistant Controller from May 2016 to October 2017. He served as a Financial Consultant at Marketo, Inc., a marketing software company from March 2016 to May 2016. Mr. Kalkofen served as President and Vice President of Finance, Consultant at Simplifier Corporation, a SaaS expense reporting solutions company, which he co-founded, from October 2014 to May 2016. He also held positions with Symantec Corporation, a cybersecurity software company, from 2012 through October 2014. Mr. Kalkofen's experience also includes serving as CFO of Pinnacle Bank in Oregon from 2002 to 2007 and CFO of Westcoast Bancorp from 1992 to 2000. He began his career at PricewaterhouseCoopers LLP as part of the firm's audit practice group. Mr. Kalkofen holds a B.A. in Accounting from Washington State University, is an active Certified Public Accountant and Certified Global Management Accountant.
Donald Kalkofen is 56, he's been the Chief Financial Officer e Principal Financial Officer and Principal Accounting Officer of Protagonist Therapeutics Inc since 2019. There are 15 older and 4 younger executives at Protagonist Therapeutics Inc. The oldest executive at Protagonist Therapeutics Inc is Dr. David Y. Liu, 71, who is the Chief Scientific Officer and Head of Discovery & Pre-Clinical Devel..
Donald's mailing address filed with the SEC is 7707 GATEWAY BOULEVARD, SUITE 140, , NEWARK, CA, 94560.
Over the last 8 years, insiders at Protagonist Therapeutics Inc have traded over $11,629,969 worth of Protagonist Therapeutics Inc stock and bought 3,007,840 units worth $35,519,073 . The most active insiders traders include Capital Partners Gp, L.L.C...., & Johnson Johnson & Johnson... e X L.P.Canaan Partners X Llc.... On average, Protagonist Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $2,387,307. The most recent stock trade was executed by William D. Waddill on 24 July 2024, trading 8,000 units of PTGX stock currently worth $103,040.
protagonist therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform which is utilized to discover and develop novel peptide-based drugs to address significant unmet medical needs. its primary focus is on developing potential first-in-class oral targeted therapy-based peptide drugs that work by blocking biological pathways that are currently targeted by marketed injectable antibody drugs. protagonist's initial lead peptide product candidates, ptg-100 and ptg-200, are based on this approach, and the company believes these candidates have the potential to transform the existing treatment paradigm for inflammatory bowel disease (ibd), consisting primarily of ulcerative colitis and crohn's disease. ptg-100, a potential first-in-class oral peptide alpha-4-beta-7 integrin antagonist, is currently in a global phase 2b clinical trial for treatment of moderate-to-severe ulcerative colitis. ptg-200, a first-in-class oral interleukin-23 receptor antagonist
Protagonist Therapeutics Inc executives and other stock owners filed with the SEC include: